Autopsy report · NCT04635527
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
Cause of deathFunding or business
“Due to the company's development strategy adjustment ,Innovent Bioligics decided not to continue the study after consultation with investigators.”
Life of this trial
- Registered 1 month before it started.
- Ran for about 2 years 2 months before it stopped.
- 10 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Conditions
- Hepatocellular Carcinoma
- Interventions
- IBI318; cTACE; placebo
- Participants
- 10
- Sites
- 1
- Countries
- China
Trials that died the same way
- A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19
“Due to the company's development strategy adjustment, Innovant Biologics decided not to continue this study after consultation with investigators.” - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
“The study was withdrawn because BioMarin decided to end the overall development program. The study withdrawal was not due to any patient safety concerns.” - MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
“Drug provider decided not to move forward with the study.” - To Compare the Efficacy of I.V 200 mg Iron Sucrose and 500 mg Iron Sucrose to Treat Anemia in Pregnancy
“The investigators decided not to proceed with this study” - Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid
“The Investigator decided not to pursue this study.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.